United States · FDA National Drug Code directory
Flucelvax
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 87063-299_5a564edc-83a3-1611-e063-6294a90a0b80
- Product NDC
- 87063-299
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- INFLUENZA A VIRUS A/Tasmania/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Tasmania/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Arizona/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)
- Labeler
- ASCLEMED USA INC.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260701 / 20270731
Source-listed ingredients
- INFLUENZA A VIRUS A/TASMANIA/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
- INFLUENZA A VIRUS A/TASMANIA/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
- INFLUENZA B VIRUS - B/ARIZONA/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 SYRINGE, GLASS in 1 CARTON (87063-299-10) / .5 mL in 1 SYRINGE, GLASS (87063-299-01) · 87063-299-10
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →